Trapping the DNA-copying machine: a probe to film transcription in real time

An excellent phase structure is presented, with clear GO/NO-GO/PIVOT criteria, allowing the project to be halted before unnecessary expenditure if the fundamental hypotheses fail. The initial computational phase is a prudent decision to test the hypothesis at low cost.

The ambition of applying the ABPP methodology to the transcription machinery is conceptually audacious and, if successful, would provide a tool of inestimable value for transcription biology, enabling precise spatiotemporal labelling of active Pol II beyond the limitations of antibody or protein-fusion approaches.

The idea of using bioorthogonality to label an engaged RNA polymerase specifically is conceptually elegant and, if it were to function, would resolve a genuine problem in transcription dynamics.

A niche but well-identified market: biotechnology and pharmaceutical companies developing transcription inhibitors (e.g., Syros Pharmaceuticals, Foghorn Therapeutics) and CROs specialising in epigenetics (e.g., Reaction Biology, Eurofins) would pay for a target validation and candidate drug screening tool targeting Pol II and its regulators (CDK7, CDK9, etc.). The addressable market size is estimated at 50–80 M$ (research tools plus associated services).

The mechanistic hypothesis is clearly stated and falsifiable, with an innovative molecular design combining α-amanitin and bioorthogonal chemistry (SPAAC) for covalent labelling in living cells.